Table 1 Characteristics of UK individuals presenting with COVID-19, during periods of Alpha and Delta SARS-CoV-2 variant predominance.

From: COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study

 

Cohort 1 (Alpha)

Cohort 2 (Delta)

Number of individuals

3581

3581

Age in years (median, (IQR))

40 (26–52)

40 (26–52)

Males (%)

41.0

41.0

BMI (kg/m2) (median, (IQR))

25.1 (22.4–29.0)

24.3 (21.9–27.8)

Vaccination status at time of positive test (numbers with 0/1/2 doses, (%))

3552 (99.2)/29 (0.8)/0 (0.0)

1183 (33.0)/881 (24.6)/1517 (42.4)

Diabetes (n, (%))

77 (2.2)

43 (1.2)

Asthma (n, (%))

488 (13.6)

465 (13.0)

Lung Disease (n, (%))

340 (9.5)

311 (8.7)

Kidney disease (n, (%))

17 (0.5)

20 (0.6)

Heart disease (n, (%))

45 (1.3)

48 (1.3)

Number of individuals with illness duration ≥ 28 days (n, (%))

380 (10.6)

311 (8.7)

Number of symptoms in the first week (median, (IQR))a

4 (3–6)

5 (3–7)

  1. aNumber of symptoms here considered from the 14 symptoms used in the analysis presented in Sudre et al. (viz.: fatigue, headache, dyspnoea, anosmia/dysosmia, persistent cough, sore throat, fever, myalgias, anorexia (‘skipped meals’), chest pain [otherwise undefined], diarrhoea, hoarse voice, abdominal pain and delirium)17.
Back to article page